drugset / Trial / NCT03232892
Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer
Phase 2
Terminated
1 enrolled
University of California, San Francisco
American Cancer Society, Inc. · collabNovartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
Phase II trial to evaluate trametinib in patients with locally advanced non-squamous, non-small cell lung cancer (NSCLC) whose tumors harbor a non-synonymous NF-1 mutation, with progressive disease on at least one prior line of therapy.
Timeline
- Start
- 2018-02-13
- Primary completion
- 2019-09-11
- Completion
- 2019-09-11
Outcome
Outcome not reported
Stopped (Enrollment): “Low Accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trametinib | Small molecule | 2 mg | Oral |